一家无产品、无营收、无利润仅有121名员工的南京Biotech,借力港股18A政策在香港资本市场IPO上市81天后,企业市值就一举超越了港股18A中的康方生物和拥有逾10款上市产品的行业龙头信达生物。(港股18A“盘子”最大的10家Biotech)这究竟是价值发现,还是资本泡沫?2025年9月15日,港股市场创下了一个历史纪录。长期位列港股18A市值“二哥”宝座的信达生物,其市值被上市仅81天的...
Source Link一家无产品、无营收、无利润仅有121名员工的南京Biotech,借力港股18A政策在香港资本市场IPO上市81天后,企业市值就一举超越了港股18A中的康方生物和拥有逾10款上市产品的行业龙头信达生物。(港股18A“盘子”最大的10家Biotech)这究竟是价值发现,还是资本泡沫?2025年9月15日,港股市场创下了一个历史纪录。长期位列港股18A市值“二哥”宝座的信达生物,其市值被上市仅81天的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.